SCHEMBL20062883

SCHEMBL20062883

Cc1cc(C)nc(N2/C(=C3/N(c4cc(C)cc(C)n4)c4ccc(C(C)(C)C)cc4N3c3cc(C)cc(C)n3)N(c3cc(C)cc(C)n3)c3cc(C(C)(C)C)ccc32)c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
KDM4E B2RXH2 1/20 0.34
LMNA P02545 1/20 0.34
NPC1 O15118 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
RAB9A P51151 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
TSHR P16473 1/20 0.32
GBA1 P04062 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
EGFR P00533 1/20 0.30
MET P08581 1/20 0.30
HCRTR1 O43613 1/20 0.30
HCRTR2 O43614 1/20 0.30
NOS3 P29474 1/20 0.30
NOS1 P29475 1/20 0.30
NOS2 P35228 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20071868 0.89
SCHEMBL20062926 0.80 HCRTR1 (0.39) ALDH1A1SMN1; SMN2KDM4ELMNANPC1
SCHEMBL20062907 0.80 ALDH1A1 (0.36) ALDH1A1SMN1; SMN2KDM4ELMNANPC1
SCHEMBL20062888 0.78 ALDH1A1 (0.30) ALDH1A1HPGD
SCHEMBL20062886 0.73 NR1H3 (0.33)
SCHEMBL19343033 0.73 HRH3 (0.36) MEN1KMT2A
SCHEMBL18905685 0.71 KCNH2 (0.36) ALDH1A1SMN1; SMN2NPC1MAPTHPGD
SCHEMBL20062928 0.71 HSD17B10 (0.32) ALDH1A1HPGDTSHR
SCHEMBL20062918 0.71 HPGD (0.32) ALDH1A1HPGDTSHR
SCHEMBL18905679 0.71 CA9 (0.39) ALDH1A1SMN1; SMN2LMNANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10193084-B2 2,2′-bibenzo[D]imidazolidene compound having heteromonocyclic groups at the 1-, 1′-, 3- and 3′- positions, and organic light-emitting element and display device containing the same CANON KABUSHIKI KAISHA (JP) 2019-01-29 US disclosed
US-20180108691-A1 ORGANIC PHOTOELECTRIC CONVERSION ELEMENT, OPTICAL AREA SENSOR, IMAGING DEVICE, AND IMAGING APPARATUS CANON KABUSHIKI KAISHA (JP) 2018-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10193084-B2 2,2′-bibenzo[D]imidazolidene compound having heteromonocyclic groups at the 1-, 1′-, 3- and 3′- positions, and organic light-emitting element and display device containing the same BRD1, DRD1, NR2E3 ALDH1A1 395/4885SMN1; SMN2 2289/4885KDM4E 3246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.